[{"id":"727643b8-a896-41d1-b305-2893939501cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04631744","created_at":"2021-01-19T20:36:38.297Z","updated_at":"2025-02-25T17:30:30.138Z","phase":"Phase 2","brief_title":"Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)","source_id_and_acronym":"NCT04631744","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" FLT3 • NTRK2 • AXL • KDR • FLT1 • FLT4","pipe":"","alterations":" ","tags":["FLT3 • NTRK2 • AXL • KDR • FLT1 • FLT4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/03/2021","start_date":" 03/03/2021","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-01-31"},{"id":"4629442d-297c-4cea-ba12-8b6c1e5ff2c5","acronym":"LENVABLA","url":"https://clinicaltrials.gov/study/NCT05113186","created_at":"2021-11-09T12:53:04.452Z","updated_at":"2025-02-25T13:35:59.564Z","phase":"Phase 2","brief_title":"Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous Ablative","source_id_and_acronym":"NCT05113186 - LENVABLA","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" AFP • FLT4 • VEGFC","pipe":"","alterations":" ","tags":["AFP • FLT4 • VEGFC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 02/02/2022","start_date":" 02/02/2022","primary_txt":" Primary completion: 07/02/2025","primary_completion_date":" 07/02/2025","study_txt":" Completion: 10/02/2026","study_completion_date":" 10/02/2026","last_update_posted":"2024-08-01"},{"id":"cd9b7f99-c8f6-4abc-a477-355dc349deae","acronym":"DUMELEP","url":"https://clinicaltrials.gov/study/NCT06045975","created_at":"2024-04-09T17:42:37.188Z","updated_at":"2025-02-25T15:01:05.349Z","phase":"Phase 2","brief_title":"Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation","source_id_and_acronym":"NCT06045975 - DUMELEP","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" FLT4 • VEGFC","pipe":"","alterations":" ","tags":["FLT4 • VEGFC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/28/2024","start_date":" 03/28/2024","primary_txt":" Primary completion: 09/28/2026","primary_completion_date":" 09/28/2026","study_txt":" Completion: 09/28/2027","study_completion_date":" 09/28/2027","last_update_posted":"2024-07-31"},{"id":"369a58dd-4a69-448b-9669-35759434dc53","acronym":"TWICE-IRI","url":"https://clinicaltrials.gov/study/NCT04392479","created_at":"2021-01-18T21:11:59.050Z","updated_at":"2024-07-02T16:35:32.165Z","phase":"Phase 3","brief_title":"TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.","source_id_and_acronym":"NCT04392479 - TWICE-IRI","lead_sponsor":"GCS IHFB Cognacq-Jay","biomarkers":" KDR • FLT4 • VEGFC","pipe":"","alterations":" ","tags":["KDR • FLT4 • VEGFC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • leucovorin calcium • Zaltrap (ziv-aflibercept IV)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 202","initiation":"Initiation: 09/02/2020","start_date":" 09/02/2020","primary_txt":" Primary completion: 06/15/2023","primary_completion_date":" 06/15/2023","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-10-23"},{"id":"f86fbabb-dbbe-4ed0-8d46-9e3047621d9b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05114668","created_at":"2021-11-10T14:12:50.487Z","updated_at":"2024-07-02T16:35:47.602Z","phase":"Phase 1","brief_title":"Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours","source_id_and_acronym":"NCT05114668","lead_sponsor":"Kazia Therapeutics Limited","biomarkers":" FLT4","pipe":"","alterations":" ","tags":["FLT4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EVT801"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 11/03/2021","start_date":" 11/03/2021","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-05-19"},{"id":"863f301c-d7ce-401c-a561-44e816aa2de5","acronym":"BOOSTER","url":"https://clinicaltrials.gov/study/NCT01989780","created_at":"2021-01-18T09:04:26.431Z","updated_at":"2024-07-02T16:36:06.061Z","phase":"Phase 2","brief_title":"Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer","source_id_and_acronym":"NCT01989780 - BOOSTER","lead_sponsor":"Japan Breast Cancer Research Group","biomarkers":" HER-2 • ER • KDR • FLT1 • FLT4 • VEGFC • FGF","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER • KDR • FLT1 • FLT4 • VEGFC • FGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • paclitaxel • fulvestrant • letrozole • anastrozole • exemestane • goserelin acetate • leuprolide acetate for depot suspension"],"overall_status":"Completed","enrollment":" Enrollment 160","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 06/01/2019","study_completion_date":" 06/01/2019","last_update_posted":"2022-08-04"},{"id":"94fabb12-5332-4639-9c1b-0c494b08b3f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT01999972","created_at":"2021-01-18T09:07:42.631Z","updated_at":"2024-07-02T16:36:40.719Z","phase":"Phase 1b","brief_title":"A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT01999972","lead_sponsor":"Pfizer","biomarkers":" MET • HGF • FLT4","pipe":" | ","alterations":" MET positive","tags":["MET • HGF • FLT4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • axitinib"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 02/26/2014","start_date":" 02/26/2014","primary_txt":" Primary completion: 02/22/2017","primary_completion_date":" 02/22/2017","study_txt":" Completion: 09/05/2019","study_completion_date":" 09/05/2019","last_update_posted":"2020-09-24"},{"id":"f76845b1-ea5c-4ee7-9b14-d75b2ede7244","acronym":"","url":"https://clinicaltrials.gov/study/NCT01514123","created_at":"2021-01-18T06:21:50.486Z","updated_at":"2024-07-02T16:36:40.929Z","phase":"Phase 1","brief_title":"Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT01514123","lead_sponsor":"Circadian Technologies Ltd.","biomarkers":" KDR • FLT4 • VEGFD • VEGFC","pipe":"","alterations":" ","tags":["KDR • FLT4 • VEGFD • VEGFC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab)"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 12/29/2011","start_date":" 12/29/2011","primary_txt":" Primary completion: 02/07/2014","primary_completion_date":" 02/07/2014","study_txt":" Completion: 11/16/2017","study_completion_date":" 11/16/2017","last_update_posted":"2020-09-17"},{"id":"d6d64b89-f7f7-4bec-a903-6fffbe1ea5b6","acronym":"DISTINCTIVE","url":"https://clinicaltrials.gov/study/NCT04252456","created_at":"2021-01-18T20:39:55.170Z","updated_at":"2024-07-02T16:36:50.523Z","phase":"","brief_title":"Folfiri/aflIbercept in Metastatic coloreCTal Cancer patIents With RAS Validated Wild typE Status","source_id_and_acronym":"NCT04252456 - DISTINCTIVE","lead_sponsor":"Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente","biomarkers":" KDR • RAS • FLT4 • IL1A","pipe":" | ","alterations":" RAS wild-type","tags":["KDR • RAS • FLT4 • IL1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • leucovorin calcium • Zaltrap (ziv-aflibercept IV)"],"overall_status":"Unknown status","enrollment":" Enrollment 150","initiation":"Initiation: 04/23/2018","start_date":" 04/23/2018","primary_txt":" Primary completion: 04/01/2020","primary_completion_date":" 04/01/2020","study_txt":" Completion: 02/01/2021","study_completion_date":" 02/01/2021","last_update_posted":"2020-02-05"},{"id":"d5003fdf-f2e7-4d91-8e0b-f087be500f33","acronym":"","url":"https://clinicaltrials.gov/study/NCT00569946","created_at":"2021-01-18T02:04:49.928Z","updated_at":"2024-07-02T16:36:59.082Z","phase":"Phase 2","brief_title":"Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)","source_id_and_acronym":"NCT00569946","lead_sponsor":"Pfizer","biomarkers":" KIT • KDR • VEGFA • FLT1 • FLT4","pipe":"","alterations":" ","tags":["KIT • KDR • VEGFA • FLT1 • FLT4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e axitinib"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 12/12/2007","start_date":" 12/12/2007","primary_txt":" Primary completion: 02/26/2010","primary_completion_date":" 02/26/2010","study_txt":" Completion: 10/30/2012","study_completion_date":" 10/30/2012","last_update_posted":"2019-06-05"},{"id":"9e38132f-f6aa-4337-816d-1a1db58ab598","acronym":"","url":"https://clinicaltrials.gov/study/NCT00835978","created_at":"2021-01-18T03:10:54.824Z","updated_at":"2024-07-02T16:37:21.625Z","phase":"Phase 2","brief_title":"Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer","source_id_and_acronym":"NCT00835978","lead_sponsor":"Pfizer","biomarkers":" FLT4 • MCAM • CD31 • ENG • PECAM1","pipe":"","alterations":" ","tags":["FLT4 • MCAM • CD31 • ENG • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e axitinib"],"overall_status":"Completed","enrollment":" Enrollment 213","initiation":"Initiation: 08/01/2009","start_date":" 08/01/2009","primary_txt":" Primary completion: 10/01/2012","primary_completion_date":" 10/01/2012","study_txt":" Completion: 02/01/2016","study_completion_date":" 02/01/2016","last_update_posted":"2017-05-30"}]